Impact of Comorbidities and Skin Diseases on Post-Vaccination Reactions: A Study on COVID-19 Vaccinations in Poland

Overview

Journal J Clin Med

Specialty General Medicine

Date 2024 Oct 26

PMID 39458123

Authors

Izabela Jeskowiak-Kossakowska

Paulina Nowotarska

Patrycja Grosman-Dziewiszek

Adam Szelag

Benita Wiatrak

Affiliations

Soon will be listed here.

Abstract

The COVID-19 pandemic necessitated rapid and widespread vaccination efforts, which proved critical in reducing the severity and mortality of the virus. However, the interplay between vaccinations, pre-existing skin conditions, and other comorbidities still needs to be explored. This study investigated the occurrence and severity of adverse events following immunization (AEFIs) with COVID-19 vaccines in individuals with chronic skin diseases and comorbidities within a Central European cohort. An anonymous online survey was conducted between May 2022 and February 2023, targeting students and employees of universities in Wrocław, Poland. A total of 513 respondents were analyzed, focusing on AEFIs following the first, second, and third doses of COVID-19 vaccines and the effects of COVID-19 on conditions such as atopic dermatitis, psoriasis, vitiligo, acne vulgaris, rosacea, and various comorbidities. COVID-19 vaccination effectively protected against severe disease across all doses. The analysis revealed no significant impact of either COVID-19 infection or vaccination on the course of selected skin diseases and comorbidities. The reporting of AEFIs to the Sanitary Inspection was notably low. The Moderna and Pfizer mRNA-based vaccines were associated with a higher reported number of AEFIs, particularly after the second and third doses, compared to AstraZeneca, which exhibited fewer adverse events after subsequent doses. COVID-19 vaccination is both safe and effective, even in patients with pre-existing skin conditions and comorbidities. Vaccine selection may benefit from considering individual health profiles, and better reporting of AEFIs is needed to enhance vaccine safety monitoring.

References

Nassar R, Alnatour D, Thiab S, Nassar A, El-Hajji F, Basheti I . Short-term side effects of COVID-19 vaccines: A cross-sectional study in Jordan. Hum Vaccin Immunother. 2022; 18(5):2082792. PMC: 9621041. DOI: 10.1080/21645515.2022.2082792. View

Wasserbauer M, Hlava S, Trojanek M, Stovicek J, Milota T, Drabek J . Efficacy and safety of SARS-CoV-2 vaccination in patients with inflammatory bowel disease on immunosuppressive and biological therapy: Prospective observational study. PLoS One. 2022; 17(9):e0273612. PMC: 9439210. DOI: 10.1371/journal.pone.0273612. View

Hren M, Khattri S . Low rates of vaccination among atopic dermatitis, alopecia areata, psoriasis, and psoriatic arthritis patients on biologics. Arch Dermatol Res. 2024; 316(6):285. DOI: 10.1007/s00403-024-03037-6. View

Hussain Awan M, Samreen S, Salim B, Gul H, Perveen S, Nasim A . Corona Virus Disease-19 Vaccine-associated Autoimmune Disorders. Rheumatol Immunol Res. 2023; 3(3):111-119. PMC: 9895874. DOI: 10.2478/rir-2022-0019. View

Zhang Y, Chen H, Lv J, Huang T, Zhang R, Zhang D . Evaluation of Immunogenicity and Safety of Vero Cell-Derived Inactivated COVID-19 Vaccine in Older Patients with Hypertension and Diabetes Mellitus. Vaccines (Basel). 2022; 10(7). PMC: 9315836. DOI: 10.3390/vaccines10071020. View

Valera-Rubio M, Sierra-Torres M, Castillejo Garcia R, Cordero-Ramos J, Lopez-Marquez M, Cruz-Salgado O . Adverse events reported after administration of BNT162b2 and mRNA-1273 COVID-19 vaccines among hospital workers: a cross-sectional survey-based study in a Spanish hospital. Expert Rev Vaccines. 2022; 21(4):533-540. PMC: 8787836. DOI: 10.1080/14760584.2022.2022478. View

Chen C, Huang S, Geng L, Lai P, Dou H, Zhang H . COVID-19 vaccination and infection status: a cross-sectional survey of patients with rheumatic diseases in China. Rheumatol Int. 2023; 44(4):703-713. DOI: 10.1007/s00296-023-05438-8. View

Shi X, Sun Y, Ding X . Impact of COVID-19 Vaccine and COVID-19 Infection on Vitiligo Activity and Progression. Clin Cosmet Investig Dermatol. 2023; 16:3581-3587. PMC: 10729677. DOI: 10.2147/CCID.S439045. View

Wang Q, Lv C, Han X, Shen M, Kuang Y . A Web-Based Survey on Factors for Unvaccination and Adverse Reactions of SARS-CoV-2 Vaccines in Chinese Patients with Psoriasis. J Inflamm Res. 2021; 14:6265-6273. PMC: 8636842. DOI: 10.2147/JIR.S341429. View

10.

Kridin K, Schonmann Y, Onn E, Tzur Bitan D, Weinstein O, Cohen A . Determinants and Effectiveness of BNT162b2 mRNA Vaccination Among Patients with Atopic Dermatitis: A Population-Based Study. Am J Clin Dermatol. 2022; 23(3):385-392. PMC: 8924351. DOI: 10.1007/s40257-022-00672-5. View

11.

Cantisani C, Chello C, Grieco T, Ambrosio L, Kiss N, Tammaro A . Cutaneous Reactions to COVID-19 Vaccines in a Monocentric Study: A Case Series. J Clin Med. 2022; 11(13). PMC: 9267144. DOI: 10.3390/jcm11133811. View

12.

Rogers A, Rooke E, Morant S, Guthrie G, Doney A, Duncan A . Adverse events and overall health and well-being after COVID-19 vaccination: interim results from the VAC4COVID cohort safety study. BMJ Open. 2022; 12(6):e060583. PMC: 9160588. DOI: 10.1136/bmjopen-2021-060583. View

13.

Graceffa D, Sperati F, Bonifati C, Spoletini G, Lora V, Pimpinelli F . Immunogenicity of three doses of anti-SARS-CoV-2 BNT162b2 vaccine in psoriasis patients treated with biologics. Front Med (Lausanne). 2022; 9:961904. PMC: 9485492. DOI: 10.3389/fmed.2022.961904. View

14.

Bian S, Li L, Wang Z, Cui L, Xu Y, Guan K . Allergic Reactions After the Administration of COVID-19 Vaccines. Front Public Health. 2022; 10:878081. PMC: 9152252. DOI: 10.3389/fpubh.2022.878081. View

15.

Duijster J, Lieber T, Pacelli S, Van Balveren L, Ruijs L, Raethke M . Sex-disaggregated outcomes of adverse events after COVID-19 vaccination: A Dutch cohort study and review of the literature. Front Immunol. 2023; 14:1078736. PMC: 9922710. DOI: 10.3389/fimmu.2023.1078736. View

16.

Yoon D, Jeon H, Noh Y, Choe Y, Choe S, Jung J . A Nationwide Survey of mRNA COVID-19 Vaccinee's Experiences on Adverse Events and Its Associated Factors. J Korean Med Sci. 2023; 38(22):e170. PMC: 10244024. DOI: 10.3346/jkms.2023.38.e170. View

17.

Lindgren A, Austin A, Welsh K . COVID Arm: Delayed Hypersensitivity Reactions to SARS-CoV-2 Vaccines Misdiagnosed as Cellulitis. J Prim Care Community Health. 2021; 12:21501327211024431. PMC: 8202256. DOI: 10.1177/21501327211024431. View

18.

Bots S, Riera-Arnau J, Belitser S, Messina D, Aragon M, Alsina E . Myocarditis and pericarditis associated with SARS-CoV-2 vaccines: A population-based descriptive cohort and a nested self-controlled risk interval study using electronic health care data from four European countries. Front Pharmacol. 2022; 13:1038043. PMC: 9730238. DOI: 10.3389/fphar.2022.1038043. View

19.

Du Y, Chen L, Shi Y . Safety, Immunogenicity, and Efficacy of COVID-19 Vaccines in Adolescents, Children, and Infants: A Systematic Review and Meta-Analysis. Front Public Health. 2022; 10:829176. PMC: 9046659. DOI: 10.3389/fpubh.2022.829176. View

20.

Hou X, Wu N, Xu M, Kharel P, Wu F, Wu Y . Demographic and clinical feature disparity between progress and non-progress patients with vitiligo after COVID-19 vaccination: A cross-sectional study. Exp Dermatol. 2023; 32(9):1344-1349. DOI: 10.1111/exd.14825. View